Aktie 603739 QINGDAO VLAND BIOTECH INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Qingdao Vland Biotech INC.

Aktien

603739

CNE100003GX8

603739

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 28.06.2024 		% 5 Tage % 1. Jan.
12.92 CNY -0.15% Intraday Chart für Qingdao Vland Biotech INC. -3.87% -15.11%
07.05. Chinesische Aktien geben leicht nach; Hongkong-Aktien fallen nach 10-tägiger Gewinnserie RE
25.04. Qingdao Vland Biotech INC. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
China stocks edge down; HK shares fall after 10-day winning streak
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders.
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million.
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd.
Archer Daniels Midland : to Create Human Probiotics Joint Venture With Qingdao Vland Biotech Group
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 603739 Aktie
  4. Nachrichten Qingdao Vland Biotech INC.
  5. Andere Sprachen